Anselamimab - CAS 2414866-63-8

Anselamimab is a humanized IgG1κ monoclonal antibody targeting serum amyloid A1 (SAA1) . It removes amyloid deposits by specifically binding to amyloid fibrils and triggering phagocytosis by macrophages and neutrophils.Anselamimab was used as an APP (β-amyloid A4 Protein Precursor) inhibitor in the clinical phase for the treatment of light chain (AL) amyloidosis.

Apolipoprotein, Beta Amyloid

Metabolism, Neuroscience

2414866-63-8

0.98

-20°C

Ice Packs

Inhibitory Antibodies